← Leaderboards
Donna M Peehl
Stanford University
$4,923,077
Attributed
$8,820,104
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2006–24$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,820,104 · 3
By mechanism
U24$3,430,714 · 1
U01$3,219,768 · 1
R01$2,169,622 · 1
Top collaborators
- John Kurhanewicz13 shared
- Renuka Sriram8 shared
Most similar at Stanford University
Same institution · by research overlap
- Joseph C Wu$80,370,369
- Calvin J Kuo$48,363,495
- Mark A Kay$46,920,488
- Ronald Levy$27,846,042
- Scott L Delp$38,724,527
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsBiological MarkersTumor XenograftPathway InteractionsTechnologySerumMagnetic ResonanceGeneticMalignant Neoplasm Of ProstatePathologicResistanceProgramsResourcesResponseClinical TrialsImageImaging ApproachImaging TechniquesMagnetic Resonance ImagingTranscriptomicsMetabolicMetabolic ImagingBiopsyUnited States National Institutes Of Health
Grant awards (18)
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI$626,274
U24 · FY2024 · CA
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI$656,819
U24 · FY2023 · CA
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI$74,419
U24 · FY2023 · CA
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI$656,818
U24 · FY2022 · CA
Characterization of PDX SCNC prostate cancer metastatic murine models and development of associated research resources$75,937
U24 · FY2022 · CA
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI$670,222
U24 · FY2021 · CA
Metabolic imaging comparisons of patient-derived models of renal cell carcinoma$633,577
U01 · FY2021 · CA
Preclinical imaging characterization and resource development of PDX SCNC prostate cancer murine models$1
U24 · FY2021 · CA
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI$670,224
U24 · FY2020 · CA
Metabolic imaging comparisons of patient-derived models of renal cell carcinoma$633,577
U01 · FY2020 · CA
Metabolic imaging comparisons of patient-derived models of renal cell carcinoma$626,261
U01 · FY2019 · CA
Metabolic imaging comparisons of patient-derived models of renal cell carcinoma$651,395
U01 · FY2018 · CA
Metabolic imaging comparisons of patient-derived models of renal cell carcinoma$674,958
U01 · FY2017 · CA
A Serum Marker for Aggressive Prostate Cancer$448,648
R01 · FY2010 · CA · contact PI
A Serum Marker for Aggressive Prostate Cancer$439,850
R01 · FY2009 · CA · contact PI
A Serum Marker for Aggressive Prostate Cancer$427,039
R01 · FY2008 · CA · contact PI
A Serum Marker for Aggressive Prostate Cancer$422,810
R01 · FY2007 · CA · contact PI
A Serum Marker for Aggressive Prostate Cancer$431,275
R01 · FY2006 · CA · contact PI